The present invention relates to the use of type I polymerized collagen in Covid-19 positive patients and to an intramuscular dosing regimen every 12 h for 3 days and then every 24 h for 4 days in patients with mild to moderate Covid-19 disease, or an intramuscular dosing regimen every 12 h for 7 days in patients with severe to semi-critical illness due to Covid-19. In addition, the clinical evolution of each patient was analyzed individually (Figures 13 to 17 and 20 to 21) and in groups (Figures 18 and 19), taking into account the following parameters: percentage of SpO2, temperature, heart rate, respiratory rate, cough intervals, chest pain, headache, dyspnea, odynophagia, anosmia, loss of sense of taste, and presence of arthralgia and myalgia; clinical improvement was documented in all cases.
展开▼
